STAT3 and breast cancer: Another study involving ExomiR-155 showed that it inhibits SOCS6, activating the JAK2/STAT3 signaling pathway leading to the proliferation and differentiation of SKBR3 cells and MCF-7, which ultimately results in breast cancer cells becoming resistant to tamoxifen (Shen et al., 2015).